Welcome to our dedicated page for Neurobo Pharmaceuticals SEC filings (Ticker: NRBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading NeuroBo Pharmaceuticals’ clinical disclosures can feel like untangling lab notes—hundreds of pages of receptor pharmacology, trial protocols and risk factors that shift with every phase update. Identifying what really moves the stock, from cash-runway details to management’s option grants, is a challenge even for seasoned analysts.
Stock Titan solves that problem in seconds. Our AI transforms NeuroBo Pharmaceuticals SEC filings explained simply: it condenses the annual report into an easy scan, flags key data in the NeuroBo Pharmaceuticals annual report 10-K simplified, and pairs each NeuroBo Pharmaceuticals quarterly earnings report 10-Q filing with trend visuals on R&D spend. Real-time alerts surface NeuroBo Pharmaceuticals Form 4 insider transactions real-time, while pipeline milestones in every NeuroBo Pharmaceuticals 8-K material events explained arrive on your dashboard moments after hitting EDGAR.
Here’s what you can explore without wading through biotech jargon:
- Insider activity – track NeuroBo Pharmaceuticals insider trading Form 4 transactions and spot buying patterns before pivotal data drops.
- Pipeline catalysts – AI highlights trial results, FDA interactions and financing moves within each 8-K.
- Cash & compensation – compare burn-rate disclosures in 10-Qs with the NeuroBo Pharmaceuticals proxy statement executive compensation to align incentives.
- Event-driven research – one-click access to NeuroBo Pharmaceuticals earnings report filing analysis and understanding NeuroBo Pharmaceuticals SEC documents with AI.
- Executive deals – drill into NeuroBo Pharmaceuticals executive stock transactions Form 4 in context with upcoming readouts.
Whether you’re benchmarking dual-agonist competitors or timing entries around Phase 2 data, Stock Titan’s AI-powered summaries, expert commentary and real-time feeds help you move from document download to decision—without missing a disclosure.
MetaVia Inc. Reporting persons Armistice Capital, LLC and Steven Boyd disclose beneficial ownership of 1,270,887 shares of MetaVia common stock, representing 4.99% of the class. Armistice Capital is the investment manager to Armistice Capital Master Fund Ltd., the direct holder, and exercises shared voting and dispositive power over the shares reported. Mr. Boyd, as managing member of Armistice Capital, is also reported as having shared voting and dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Woodworth Marshall H, listed as Chief Financial Officer, reported a Form 4 for MetaVia Inc. (MTVA) showing a transaction dated 08/12/2025. The filing records a transaction code G and shows acquisition of 14,200 shares at a price of $0, bringing his beneficial ownership to 30,079 shares. The Form 4 was executed by a power of attorney on 08/13/2025 and includes Exhibit 24 (Power of Attorney).
MetaVia Inc. Form 8-K — Regulation FD disclosure (Aug 6, 2025)
MetaVia furnished a press release announcing an extension of the 48 mg multiple ascending dose (MAD) cohort in the Phase 1 clinical trial of DA-1726 from 4 weeks to 8 weeks and reporting that a fifth weekly dose was administered to the first patient. DA-1726 is described as a novel dual oxyntomodulin (OXM) analog agonist acting at GLP1R and GCGR for obesity treatment.
- Date: August 6, 2025
- Action: Cohort duration extended to 8 weeks (from 4 weeks)
- Dosing update: Fifth weekly dose given to first patient
- Exhibit: Press release furnished as Exhibit 99.1 (information furnished, not filed)
FAQ
What is the current stock price of Neurobo Pharmaceuticals (NRBO)?
What is the market cap of Neurobo Pharmaceuticals (NRBO)?
